Drugs / CVM26
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06967181 | May 2025 → Dec 2027 expected | mumps infectious disease | CyanVac LLC | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CVM26 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06967181 ↗ |
| Modality | Vaccine | “CVM150 and CVM26 Intranasal Mumps Virus Vaccines” NCT06967181 ↗ |
| Route | Intranasal | “single intranasal dose of CVM150, CVM26 or intranasal saline placebo” NCT06967181 ↗ |